Dexcom diabetes monitoring refers to the use of a Dexcom continuous glucose monitor — primarily the G7 and G7 15-Day — to manage type 1, type 2, or gestational diabetes through real-time glucose data, customizable alerts, and remote data sharing with caregivers and clinicians.
For people living with diabetes, a CGM is one of the most impactful technologies of the last two decades. This guide covers how Dexcom works specifically for diabetes care, how to interpret the alerts, and when a prescription makes clinical sense.
Why CGMs Changed Diabetes Care
Before CGMs, diabetes management relied on 4-10 fingersticks a day — isolated data points with large gaps. Dexcom’s continuous data closes those gaps, revealing overnight lows, dawn-phenomenon rises, and post-meal spikes that fingersticks miss.
Landmark trials like DIAMOND and REPLACE-BG showed CGM use reduces A1C, time in hypoglycemia, and diabetes-related hospital admissions. The A1C benefit averages 0.4-0.6 percentage points, which is clinically significant. That evidence drove the ADA to recommend CGM for all insulin-using adults with diabetes.
How Dexcom Works for Diabetes
The G7 sensor inserts into the back of the upper arm (adults) or upper buttocks (pediatric patients 2-6). A 0.4 mm filament sits in interstitial fluid and reads glucose every five minutes via glucose-oxidase enzyme chemistry.
Unlike prediabetes use cases, diabetes-focused setups often rely on the full alert stack:
- High alert: Default 250 mg/dL; customizable down to 120 mg/dL.
- Low alert: Default 70 mg/dL; adjustable per patient.
- Urgent Low: Fixed at 55 mg/dL, cannot be disabled for safety.
- Urgent Low Soon: Predicts a drop to 55 mg/dL within 20 minutes.
- Rise and Fall alerts: Based on rate of change (e.g., rising 3 mg/dL/min).
Integration with Insulin Pumps and Pens
Dexcom G7 integrates with a growing list of automated insulin delivery (AID) systems. As of 2026, supported pumps include the Tandem t:slim X2 with Control-IQ, the Omnipod 5, the Beta Bionics iLet, and the Medtronic MiniMed 780G in some regions. Smart pen systems like the InPen also display Dexcom data in-app.
| System | Type | Dexcom G7 Compatible |
|---|---|---|
| Tandem t:slim X2 | AID pump | Yes (Control-IQ+) |
| Omnipod 5 | Tubeless AID pump | Yes |
| Beta Bionics iLet | Bionic pancreas | Yes |
| InPen (Medtronic) | Smart insulin pen | Yes (in-app) |
| Sequel twiist | AID pump | Yes |
Dexcom Share and Clarity
Share lets up to 10 followers view your live glucose on their phones. Parents of children with type 1, adult children of elderly parents, and partners of anyone with severe hypoglycemia risk use Share for peace of mind and emergency response. Clarity, the companion analytics app, generates Ambulatory Glucose Profile (AGP) reports that endocrinologists now routinely review at appointments.
Accuracy and Limitations
Dexcom G7 carries an overall MARD of 8.2% and meets FDA iCGM special controls, meaning it can be used to make insulin dosing decisions without a confirmatory fingerstick in most cases. Still, the FDA labeling recommends fingerstick confirmation if symptoms do not match the reading or during the first few hours of a new sensor.
Known interference sources include high-dose acetaminophen (>1,000 mg) and hydroxyurea. Dehydration, extreme cold, and rapid altitude changes can also introduce small inaccuracies.
When Dexcom Is Medically Indicated
According to ADA Standards of Care, CGM is recommended for:
- All adults with type 1 diabetes.
- All adults with type 2 diabetes using any insulin regimen.
- Children and adolescents with type 1 diabetes.
- Pregnant patients with type 1 diabetes.
- Patients with frequent or severe hypoglycemia.
For type 2 diabetes on oral agents only, CGM is increasingly offered as a short-term diagnostic and educational tool. This bridges into diet and nutrition coaching where real-time data drives food choices.
Cost and Coverage in 2026
With commercial insurance, G7 co-pays are typically $35-85 per month. Medicare Part B covers Dexcom for insulin-using beneficiaries at roughly a 20% co-insurance after deductible. Cash-pay runs $200-400 per month. Dexcom’s patient assistance programs can reduce that further for qualifying patients.
The Bottom Line
Dexcom diabetes monitoring — especially G7 and G7 15-Day — combines clinical-grade accuracy, life-saving alerts, and caregiver connectivity. If you use insulin or experience unpredictable glucose patterns, ask your clinician whether a Dexcom system fits your diabetes treatment plan. The combination of data plus action is what drives A1C reductions and a safer, more flexible life with diabetes.
This article is educational and not a substitute for personalized medical advice. Always follow your healthcare provider’s guidance on insulin dosing and CGM use.
